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http://dx.doi.org/10.1016/j.chembiol.2013.04.006Epigenetics is the study of the processes
regulating the expression of genes that
overlay DNA while not changing the
gene sequence itself. Diseases like can-
cer can ensue when this regulatory sys-
tem goes out of whack. Epigenetic
changes can also lead to acquired drug
resistance. New incarnations of older
drugs combined as epigenetic therapies,
however, could put the brakes on cancer





(HDAC) inhibitor entinostat is in phase 2‘‘Combining HDAC inhibitors with DNA methyltransferase inhibi-
torswill have a synergistic effect ongene re-expression.’’—Peter
Ordentlichtrials to determine its effectiveness in
treating metastatic breast cancer, lung
cancer, and other solid tumors. ‘‘The un-
derlying premise of the company is target-
ing resistance that happens in cancer
therapies, which is a phenomenon that
happens in almost every case, particularly
in the advanced metastatic setting,’’
said Peter Ordentlich, Ph.D, company
cofounder and vice president of transla-
tional medicine. Syndax’s strategy is to
target cancer resistance pathways with
its HDAC inhibitor plus a proven cancer
therapy. Epigenetic drugs have been
available for lymphomas or leukemia for
years. They have shown the greatest effi-
cacy in hematopoietic cancers but only
recently have been used on solid tumors
with any degree of success. They are
considered less toxic than chemotherapy.
Tie Me Up, Tie Me Down
Cell DNA is compacted in nucleosome
spools made up of eight different histone
proteins, surrounded by a compact chro-
matin casing. Epigenetically modifyinghistones by acetylation, methylation, or
phosphorylation can induce the chro-
matin to relax and open up promoter
regions to transcription factors, upregu-
lating gene transcription.
The FDA approved HDAC inhibitors
vorinostat (Zolinza) and romidepsin (Isto-
dax) in 2007 and 2009, respectively, to
treat cutaneous T cell lymphoma (CTCL).
HDACs prevent histone acetylation, relax-
ing chromatin structure leading to the
activation of genes. Azacitidine (Vidaza),
approved in 2004, and decitabine (Daco-
gen), approved in 2006, are DNA histone
methylating transferase (DNMT) inhibitors
that treat subtypes of myelodysplasticsyndrome (MDS), or preleukemia, by in-
hibiting methylation, so DNA is expressed
rather than silenced. ‘‘Combining HDAC
inhibitors with DNA methyltransferase in-
hibitors will have a synergistic effect on
gene re-expression, because you are in-
hibiting two different modes of silencing
gene re-expression, one at the level of
DNA and one at the level of the histone,’’
says Ordentlich.
Staving Off Resistance as Long as
Possible
Entinostat is currently featured in 12 clin-
ical trials for a variety of cancers. Accord-
ing to Ordentlich, there are cancer drugs
that work well and ideally one would
want to prolong their effects. For
example,70% of breast cancers are es-
trogen positive and can be treated with
adjuvant therapy if diagnosed early
enough. For metastatic cancer or cancer
that recurs after surgery, the overall sur-
vival outlook can be 3–4 months. In these
patients, hormone therapy works well as
the first line of treatment but, inevitably,Chemistry & Biology 20, April 18, 2013resistance develops. Second and third
rounds of hormone therapy work for a
while, and clinicians try to keep women
on successive cycles of hormone therapy
as long as possible before resorting to
chemotherapy as it extends the patients’
quality of life. ‘‘All of this is made possible
by understanding themolecular pathways
that affect resistance,’’ says Ordentlich.
In the mid-to-late 1990s, Ordentlich
worked in the lab of Professor Ronald
Evans, director of the Gene Expression
Laboratory at the Salk Institute. The re-
searchers found that a subset of MDS
patients became resistant to retinoid
treatment and discovered that combining
retinoids with a HDAC inhibitor could
overcome resistance.
In 2006, Ordentlich got together with
Kim Kamdar, Ph.D, of venture firm
Domain Associates, LLC (http://www.
domainvc.com), to start Syndax, which
is now a $40 million company. Looking
for a potential platform, the Syndax man-
agement team in-licensed MS-275, now
entinostat, from Bayer. At the time, the
compound had undergone an unsuccess-
ful phase 2 study in metastatic melanoma
but possessed a good safety profile,
attractive pharmacology for combina-
tions, oral dosing, and a half-life of 80–
100 hr in plasma concentration as well
as a long biochemical effect on changes
in cells because of the acetylation effect.
Entinostat is now being combined with
an aromatase inhibitor in a clinical trial
conducted by Dr. Pamela Munster, direc-
tor of the Early Phase Clinical Trials Pro-
gram at UCSF, on metastatic breast
cancer patients. Other trials include vori-
nostat paired with tamoxifen to treat
tumors that have acquired hormone
resistance. Munster has seen durable
responses in patients treated with tamox-
ifen and an HDAC, lasting up to 2 years.
‘‘We don’t know the mechanisms of
HDAC inhibitors,’’ says Munster. ‘‘HDAC
inhibitors as a single agent have been
disappointing. But when used withª2013 Elsevier Ltd All rights reserved 455
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chromatin structure. We also think that
they disable the DNA repair genes. We
know they disable the ATM signaling.
We don’t know if they are p53 dependent
or not.’’ Munster’s group wants to find
predictive biomarkers that can indicate
response to HDAC inhibitors before
enrolling patients in clinical trials,
because 45% of patients don’t respond
to HDACs. According to Munster,
although HDAC enzymes are class spe-
cific in the laboratory, it is difficult to tell
if HDAC inhibitors like vorinostat and enti-
nostat behave differently from each other
in the clinic.
Stand Up To Cancer
Entinostat and azacitidine are being
tested together in a clinical trial in an
ongoing program at Johns Hopkins spon-
sored by Stand Up To Cancer (http://
www.standup2cancer.org), a venture phi-
lanthropy organization created by a group
of powerful women in the entertainment
industry. ‘‘The cofounders group were all
people whose lives had been affected by
cancer in significant ways such as Laura
Ziskin, the legendary film producer who
lost her own battle with breast cancer in
2011, and Katie Couric, who lost her hus-
band to colorectal cancer in 1998,’’ says
SU2C cofounder Kathleen Lobb, senior
vice president of communications at the
Entertainment Industry Foundation. ‘‘The
commitment from the major television
networks was the linchpin with which we
knew we were able to raise significant
amounts of funds.’’ Since 2008, Stand
Up To Cancer (SU2C) has raised over
$100 million in three telethons.
SU2C partnered with the American As-
sociation for Cancer Research (AACR).
Nobel laureate Phillip Sharp, Ph.D.,
helped SU2C set up its scientific advisory
committee, with people like Dr. Dennis
Slamon, whose research led to the devel-
opment of herceptin, as well as other sci-
entific luminaries. In a high-stakes
competition that a reality TV producer
would envy, rival academic researchers,
clinicians, biotechs, and drug companies
vie for lucrative research grants on the
condition that they all have to collaborate
across disciplines and produce results
within 3 years. Currently, SU2C has
funded nine scientific ‘‘dream teams.’’456 Chemistry & Biology 20, April 18, 2013 ªSU2C has also set up separate awards
for younger researchers.
In 2009, the first five teamswere funded
at $9.5–$18 million over 3 years. SU2C
emphasizes grant funding significant
enough to have an impact, translational
research, cross-institutional collabora-
tion, and accountability. ‘‘We thought
3 years would be a short enough time to
get the scientists involved in bringing clin-
ical trials as soon as possible,’’ says Sung
Poblete, Ph.D., R.N., SU2C president and
CEO.Teamsare reviewedevery 6months.
According to Lobb, there is no guarantee
that teams would proceed to a second
or third year of funding if they didn’t
meet the milestones. SU2C reports scien-
tific progress updates at AACR and to
the public through its telethons and web-
site. So far, SU2C has worked with 500
scientists and 101 institutions in cross-
disciplinary collaborations—competing
against cancer instead of each other, as
SU2C puts it.
The Epigenetics Dream Team
‘‘What is interesting about this model is
that it does begin to break down barriers,
to take big ideas, driven by pipeline sci-
ence, to the bedside.’’ said Dr. Stephen
Baylin, deputy director of oncology and
medicine at The Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins,
who, with Peter Jones, Ph.D., D.Sc., di-
rector, University of Southern California/
Norris Comprehensive Cancer Center, is
heading up the Epigenetics Dream
Team. SU2C awarded the dream team
$9.1 million dollars over 3 years, which
has been extended to a no-cost fourth
year. The team is presenting trial results
combining entinostat and azacitidine at
the AACR April 2013 meeting, focusing
on lung cancer as well as breast, colon,
and MDS. So far, the lung cancer trials
have furnished the most promising re-
sults, as a few patients have shown a sur-
prisingly durable response to epigenetic
therapy, living for years—one up to
4 years. The team is initiating two new
clinical trials for patients with metastatic
non-small cell lung cancer. Previous clin-
ical trials showed that patients with
advanced non-small cell lung carcinoma
treated with low doses of azacitidine
and entinostat underwent a ‘‘priming ef-
fect’’ in which they responded better to2013 Elsevier Ltd All rights reservedchemotherapy or a new form of immuno-
therapy called immune checkpoint
blockade.
DMNT inhibitors have been around
since the late 1960s but were cytotoxic
in the clinic. In the 1990s, they were revis-
ited at lower doses that caused tolerable
side effects for preleukemia. According
to Baylin, the SU2C team found that aza-
citidine together with HDAC inhibitors has
significant antitumor effects on cancer
stem-like cells if used at nanomolar levels,
suggesting that these very low doses
can reprogram cells with specificity; how-
ever, it takes several cycles to show a
hematological response. They also are
better tolerated at lower doses. While tri-
als were conducted on patients with
advanced cancer and multiple tumors,
there is evidence that this therapy would
be effective earlier in treatment, even as
a second line therapy for solid tumors.
Baylin’s group will next investigate bio-
markers. Patients have to be cautioned
on expectations as well. ‘‘You have to be
very careful and delicate,’’ says Baylin.
‘‘You don’t want to give false hope and
promise. In no gratuitous sense, they are
the heroes. They put their lives on the
line.’’
Dream Team member Dr. Vered
Stearns, codirector of the Breast Cancer
Program, Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, is using
azacitidine with entinostat to reverse
epigenetic changes in the genome and
wake up important genes that could
make breast cancers more sensitive to
treatment. About a third of breast cancer
patients do not have estrogen receptors
on their cells. Her group is investigating
epigenetic agents that can sensitize cells
to endocrine treatment among cancer
subtypes. Stearns is recruiting hormone
resistant patients whose tumors have es-
trogen receptors for a study and has just
concluded a study of triple-negative pa-
tients, none of whom responded to treat-
ment. Estrogen receptor-positive patients
did, encouragingly, show a response in
the first stage of the study. ‘‘Women are
not losing their hair,’’ says Stearns. ‘‘Their
quality of life, we feel, is better than on
chemotherapy agents.’’Wendy Wolfson (wendywolfson@nasw.org) is a
science writer based in Southern California.
